We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

72 hedge funds and large institutions have $195M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 9

69% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 16

24% more funds holding

Funds holding: 58 → 72 (+14)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

28% less capital invested

Capital invested by funds: $270M → $195M (-$75.3M)

Holders
72
Holders Change
+14
Holders Change %
+24.14%
% of All Funds
1.8%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
23
Increased
27
Reduced
16
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$18.4M
2
PHS
PFM Health Sciences
California
+$4.27M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$3.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.02M
5
BlackRock
BlackRock
New York
+$2.08M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$5.68M
2
DM
Deerfield Management
New York
-$4.73M
3
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$2.2M
4
FCMI
Foresite Capital Management III
California
-$2.01M
5
Millennium Management
Millennium Management
New York
-$1.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
CI
26
Conning Inc
Connecticut
$1.3M +$1.98M +92,610 New
Northern Trust
27
Northern Trust
Illinois
$1.27M +$1.22M +57,120 +172%
Goldman Sachs
28
Goldman Sachs
New York
$977K +$1.23M +57,336 +466%
VIA
29
Vident Investment Advisory
Georgia
$964K +$1.47M +68,692 New
Prudential Financial
30
Prudential Financial
New Jersey
$958K +$1.46M +68,280 New
TCIM
31
TIAA CREF Investment Management
New York
$905K +$1.16M +54,119 +520%
OAM
32
Oxford Asset Management
United Kingdom
$747K +$1.14M +53,212 New
JP Morgan Chase
33
JP Morgan Chase
New York
$602K -$1.37M -64,178 -60%
SO
34
STRS Ohio
Ohio
$523K +$758K +35,400 +1,863%
American Century Companies
35
American Century Companies
Missouri
$452K -$56.6K -2,646 -8%
UOTTAIMCU
36
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$428K – – –
HHC
37
Hutchin Hill Capital
New York
$422K +$644K +30,100 New
AA
38
ALPS Advisors
Colorado
$407K +$621K +29,032 New
Bank of New York Mellon
39
Bank of New York Mellon
New York
$359K +$173K +8,063 +46%
Charles Schwab
40
Charles Schwab
California
$340K +$253K +11,833 +96%
Wells Fargo
41
Wells Fargo
California
$294K +$371K +17,330 +476%
D.E. Shaw & Co
42
D.E. Shaw & Co
New York
$271K -$19.6K -917 -5%
VEA
43
Virtus ETF Advisers
New York
$259K +$395K +18,442 New
MIM
44
Monashee Investment Management
Massachusetts
$249K +$380K +17,773 New
AIMCA
45
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$237K +$362K +16,900 New
Citadel Advisors
46
Citadel Advisors
Florida
$200K +$305K +14,245 New
Deutsche Bank
47
Deutsche Bank
Germany
$189K +$119K +5,542 +68%
Swiss National Bank
48
Swiss National Bank
Switzerland
$188K +$287K +13,400 New
TRSOTSOK
49
Teachers Retirement System of the State of Kentucky
Kentucky
$177K +$173K +8,100 +180%
AllianceBernstein
50
AllianceBernstein
Tennessee
$177K +$270K +12,600 New
1
2
3 4

JNCE Hedge Fund Activity: Q2 2017 in Review

72 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2017, worth a combined $195M — down 28% from $270M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new JNCE positions and 9 closed out — a net gain of 14 holders — while 27 added to existing stakes and 16 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $18.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $5.68M sold.

  • 72 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2017, up from 58 in Q1 2017.
  • Funds reported $195M of Jounce Therapeutics, Inc. Common Stock stock for Q2 2017, down 28% quarter-over-quarter.
  • 23 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2017 and 9 closed out, a net change of +14 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q2 2017 was Wellington Management Group, an estimated $18.4M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2017 was EcoR1 Capital, an estimated $5.68M sold.

Based on aggregated 13F filings for Q2 2017.